Lupin, Glenmark top picks in pharma space: PINC Research

PINC Research has come out with its report on pharma space. According to the research firm one can buy Lupin and Glenmark Pharma.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
Real-time Stock quotes, portfolio, LIVE TV and more.
GeStepAhead SME Special
moneycontrol.com

Home » News » Brokerage Recos - Sector Report

Sep 27, 2011, 04.20 PM | Source: Moneycontrol.com

Lupin, Glenmark top picks in pharma space: PINC Research

PINC Research has come out with its report on pharma space. According to the research firm one can buy Lupin and Glenmark Pharma.

Like this story, share it with millions of investors on M3

Lupin, Glenmark top picks in pharma space: PINC Research

PINC Research has come out with its report on pharma space. According to the research firm one can buy Lupin and Glenmark Pharma.

Post Your Comments

Share Cancel

Lupin, Glenmark top picks in pharma space: PINC Research
PINC Research has come out with its report on pharma space. According to the research firm one can buy Lupin and Glenmark Pharma .

Rupee depreciates; Q2FY12 could be marred by MTM losses: With rupee depreciating by ~10% against the USD in last one quarter we analyse the impact of the same on the Pharma sector which derives nearly 50% of its revenue from the export segment.

The key highlights are as follows:

  1. Rupee depreciation likely to have neutral impact on the OPM of the companies during Q2FY12 as rupee on an average has remained flat YoY against the USD.
  2. There could be MTM losses during the quarter for companies having short term/working capital loans as rupee has depreciated by ~10% QoQ against the USD. Further, interest cost during the quarter could also see a sharp rise.
  3. Most of the companies are likely to increase the quantum of hedges as on Sept 2011 in order to lock their export revenue at attractive rates
Sun Pharma, Cipla and Glenmark better placed: We expect Sun Pharma to be a major beneficiary of the rupee depreciation given the fact that the company derives nearly 50% of its revenues from the export segment and has lower quantum of hedges (35-37% of net exports over the next 12 months). As a result, it could increase its hedges during the quarter. Further the company has negligible exposure to foreign currency debt. Although Cipla has hedged only 25-30% of its net export revenues, it has foreign currency loan to the tune of USD50- 60mn. The company has partially hedged its short term loans and could probably report lower MTM losses. Glenmark, on the other hand, doesn’t have any forward covers which would be marginally positive on the OPM front given the fact that it derives 72% of its revenue from exports. Further, it has long term foreign currency debt to the tune of USD250mn so any MTM losses would be taken to balance-sheet. However, this quarter could witness a sharp rise in the interest cost.

DRL and Lupin to be partially benefited: DRL has covered 50-55% of its exports through debt and forward/option contracts. As a result the company could increase its hedges during the quarter. However, there could be MTM losses on foreign currency denominated short term borrowings during the quarter. On the other hand, Lupin has hedged its 65-70% of the export revenues through working capital debt and forward contracts. Subsequently, we expect interest cost to increase for the company.

Ranbaxy to have negative impact: Ranbaxy could be the worst impacted in our coverage universe due to rupee depreciation given the high level of hedges of USD750mn and foreign currency debt to the tune of USD400mn on
books.

Outlook and Valuation: We continue to maintain our Neutral stand on the sector given the rich valuations and the increasing competition in the high-margin domestic formulations business.

Our Buys: Lupin and Glenmark; Sells: Dr Reddy’s and Glaxo Pharma.

Institutional holding more than 40% in Indian cos

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click here

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Lupin, Glenmark top picks in pharma space: PINC Research

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login